Independent comparison. Not affiliated with Novo Nordisk. Not medical advice.
Ozempic vs Wegovy
Updated 30 March 2026
Same molecule. Same manufacturer. Different FDA approvals. Ozempic and Wegovy are both semaglutide made by Novo Nordisk. Ozempic is approved for type 2 diabetes at up to 2mg. Wegovy is approved for weight loss at up to 2.4mg. The differences come down to dosing, insurance coverage, and what your doctor is treating.
2mg
max weekly dose
FDA-approved for type 2 diabetes
~$935/month without insurance
2.4mg
max weekly dose
FDA-approved for weight management
~$1,350/month without insurance
The Key Difference
Ozempic and Wegovy are the exact same molecule (semaglutide). The difference is entirely regulatory. Ozempic is for diabetes and maxes at 2mg. Wegovy is for weight loss and goes to 2.4mg. Your insurance, your diagnosis, and your doctor determine which one you get prescribed.
Full Comparison
Every difference between Ozempic and Wegovy, side by side.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA approval year | 2017 | 2021 |
| FDA-approved indication | Type 2 diabetes | Chronic weight management |
| Maximum dose | 2mg per week | 2.4mg per week |
| Dose titration steps | 0.25, 0.5, 1, 2mg | 0.25, 0.5, 1, 1.7, 2.4mg |
| Time to max dose | 16 weeks | 16-20 weeks |
| Average weight loss | ~10-12% (SUSTAIN trials, 1mg) | 14.9% (STEP-1 trial, 2.4mg) |
| Monthly cost (no insurance) | ~$935 | ~$1,350 |
| Insurance for diabetes | Typically covered | Not approved for diabetes |
| Insurance for weight loss | Off-label, rarely covered | Covered with prior auth (varies) |
| Cardiovascular benefit | SUSTAIN-6 (diabetes patients) | SELECT trial (20% CV risk reduction) |
| Injection device | Multi-dose pen (4 doses per pen) | Single-dose pre-filled pen |
| Needle handling | User attaches new needle each week | Hidden needle, no handling |
| Approved for ages 12-17 | No (adults only) | Yes (since 2022) |
Medication Cost Calculator
Estimate your monthly cost based on insurance status and medical indication.
Ozempic
$935
per month
$11,220
total (12 months)
Insurance coverage
Unlikely (off-label for weight loss)
List price: $935/month. Max dose: 2mg (for diabetes).
Wegovy
$1,350
per month
$16,200
total (12 months)
Insurance coverage
Possible with prior authorization
List price: $1350/month. Max dose: 2.4mg (for weight loss).
Over 12 months, Ozempic is $4,980 cheaper in your scenario. Without insurance, Ozempic is less expensive, but it is only FDA-approved for diabetes, not weight loss.
Costs are estimates based on average US prices as of March 2026. Actual costs vary by pharmacy, location, and specific insurance plan. Insured copays assume commercial coverage with prior authorization approval. Savings cards from Novo Nordisk may further reduce copays for eligible patients.
Clinical Trial Data
Published results from the STEP program (Wegovy), SUSTAIN program (Ozempic), and the landmark SELECT cardiovascular outcomes trial.
| Trial | Drug / Dose | Patients | Duration | Weight Loss | Placebo |
|---|---|---|---|---|---|
| STEP-1 | Wegovy 2.4mg | 1,961 | 68 weeks | 14.9% | 2.4% |
| STEP-2 | Wegovy 2.4mg (with T2D) | 1,210 | 68 weeks | 9.6% | 3.4% |
| STEP-3 | Wegovy 2.4mg + behavioral therapy | 611 | 68 weeks | 16.0% | 5.7% |
| STEP-5 | Wegovy 2.4mg (2-year data) | 304 | 104 weeks | 15.2% | 2.6% |
| SELECT | Semaglutide 2.4mg (CV outcomes) | 17,604 | 174 weeks | 9.4% (+ 20% CV risk reduction) | 0.9% |
| SUSTAIN-6 | Ozempic 1mg (CV outcomes, T2D) | 3,297 | 104 weeks | 4.3% | 0.7% |
| SUSTAIN-1 | Ozempic 1mg (T2D, monotherapy) | 388 | 30 weeks | 3.7kg mean loss | 1.0kg gain |
STEP trials studied semaglutide at 2.4mg (the Wegovy dose) for weight management. SUSTAIN trials studied semaglutide at up to 1mg (Ozempic dose) for type 2 diabetes. The SELECT trial studied semaglutide 2.4mg for cardiovascular outcomes in patients with obesity.
How Semaglutide Works
Ozempic (for Diabetes)
Ozempic is a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1. In patients with type 2 diabetes, it stimulates insulin secretion when blood sugar is elevated, suppresses glucagon release, and slows gastric emptying. This results in improved A1C levels (up to 1.8% reduction) and moderate weight loss as a secondary benefit.
The maximum dose of 2mg was chosen based on the SUSTAIN clinical trial program, which focused on blood sugar control as the primary endpoint. Weight loss was a welcome side effect, but not the primary goal of the dosing regimen.
Ozempic uses a multi-dose FlexTouch pen. Each pen contains 4 weekly doses. Users attach a new NovoFine needle tip before each injection and dial the correct dose. This requires slightly more handling than a pre-filled pen.
Wegovy (for Weight Loss)
Wegovy uses the exact same semaglutide molecule but at a higher maximum dose (2.4mg vs 2mg). The additional 0.4mg pushes appetite suppression further, resulting in the 14.9% average body weight loss seen in the STEP-1 trial. The mechanism is identical: GLP-1 receptor activation reduces appetite, slows stomach emptying, and changes food reward signaling in the brain.
The SELECT trial (2023) was a landmark moment for Wegovy. It enrolled 17,604 patients and demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death). This was the first time any weight loss medication proved it could protect the heart, independent of weight loss alone.
Wegovy uses single-dose pre-filled FlexTouch pens. Each pen is used once and discarded. The needle is hidden and deploys automatically, so users never see or handle the needle. This is simpler than the Ozempic multi-dose pen.
Who Should Choose Which?
Ozempic is right if:
- You have type 2 diabetes as your primary condition
- Your insurance covers Ozempic but not Wegovy
- Your doctor is focused on blood sugar control first, weight loss second
- You are already on Ozempic and tolerating it well at 1-2mg
- You need a medication with a longer real-world track record (approved 2017)
- You want the lower-cost option without insurance ($935 vs $1,350/month)
Wegovy is right if:
- Your primary goal is weight loss (not diabetes management)
- You want the higher 2.4mg dose for maximum weight loss
- You have cardiovascular risk factors (proven 20% CV risk reduction)
- Your insurance covers anti-obesity medications with prior authorization
- You prefer a simpler injection device (hidden needle, single-dose pen)
- You are a teen aged 12 to 17 (Wegovy is approved for this age group)